Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302566 | 0.91 | PDE4B (0.76) | PDE4BPDE4DLMNAPOLBTSHR | |
| SCHEMBL12108264 | 0.86 | PDE4B (0.84) | PDE4BPDE4DLMNAPOLBTSHR | |
| SCHEMBL1302743 | 0.81 | PDE4B (0.75) | PDE4BPDE4DLMNAPOLBTSHR | |
| SCHEMBL1301273 | 0.78 | PDE4B (1.00) | PDE4BPDE4D | |
| SCHEMBL12108260 | 0.74 | PDE4B (0.73) | PDE4BPDE4D | |
| SCHEMBL1302302 | 0.73 | PDE4B (0.70) | PDE4BLMNATSHRSMN1; SMN2CYP17A1 | |
| SCHEMBL12108322 | 0.71 | PDE4B (0.59) | PDE4BPDE4DCYP17A1TP53ADORA2A | |
| SCHEMBL1301812 | 0.71 | PDE4B (0.87) | PDE4BSMN1; SMN2HIF1AADORA2AADORA2B | |
| SCHEMBL12108324 | 0.70 | PDE4B (0.56) | PDE4BPDE4DCYP17A1ADORA2AADORA2B | |
| SCHEMBL1301884 | 0.69 | PDE4B (0.75) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580795-B2 | Heterocyclic compounds as phosphodiesterase inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-11-12 | — | — | US | disclosed |
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269753-A1 | HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 4/4885LMNA 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.